Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | TACR3 | P29371 | 1/20 | 0.58 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.56 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.56 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.56 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4579206 | 0.92 | GRIN2D (0.68) | FAAHKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL4576850 | 0.88 | MEN1 (0.73) | KMT2AMEN1ALDH1A1GRIN1GRIN2B | |
| SCHEMBL4591719 | 0.87 | MEN1 (0.55) | FAAHKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6369662 | 0.85 | ALDH1A1 (0.49) | FAAHKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL27608834 | 0.83 | FAAH (0.52) | FAAHKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL23682656 | 0.82 | TACR3 (0.83) | FAAHKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL6214071 | 0.82 | ALDH1A1 (0.51) | FAAHALDH1A1RAB9ASMN1; SMN2POLB | |
| SCHEMBL4580802 | 0.81 | GRIN1 (0.73) | FAAHKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL3600315 | 0.81 | FAAH (1.00) | FAAHKMT2AMEN1GRIN2DGRIN3B | |
| SCHEMBL6485095 | 0.81 | ALDH1A1 (0.64) | FAAHKMT2AMEN1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435744-B2 | Piperidine derivatives as NMDA receptor antagonists | GEDEON RICHTER VEGYESZETI GYAR RT (HU) | 2008-10-14 | — | — | US | disclosed |
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | UCB Biopharma SRL (BE) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | GRIN1, GRIN2D, GRIN2C | FAAH 835/4885KMT2A 1234/4885MEN1 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.